News
GMP certification for new large scale filling line
Oss, The Netherlands, June 28, 2021. BioConnection received today from the Dutch Healthcare Inspectorate (IGJ) the GMP certification and manufacturing license for their new large scale filling line BioConnection B.V., an independent CMO (Contract Manufacturing...
BioConnection is honoured to support VarmX
With the EU and US GMP capabilities from our facility in Oss, BioConnection is proud to assist VarmX to accelerate the GMP manufacturing trajectory and bring VMX-C001 into clinical trials and ultimately to patients who currently have limited options to effective and...
AdaptVac partners with BioConnection to manufacture their COVID-19 vaccine
BioConnection announces that it is collaborating with AdaptVac for the Drug Product manufacture of their COVID-19 vaccine in its state-of-the-art-GMP manufacturing facility in the Netherlands. AdaptVac aims to accelerate the development of safe and efficacious...
BioConnection is honoured that AIMM Therapeutics has become our customer.
With our capabilities from our facility in Oss, the Netherlands, we are able to assist AIMM Therapeutics in the development of their groundbreaking clinical phase anti-cancer therapy.
Announcement: Large scale sterile GMP production capacity available for COVID-19 programs in our EMA and US-FDA certified facility
BioConnection B.V. / Oss, The Netherlands BioConnection has sterile drug product production capacity available for COVID-19 programs BioConnection (established in 2005) is an independent CMO (Contract Manufacturing Organization). We have our own facility in Oss, The...
Announcement: Sterile GMP production capacity available to overcome Covid-19 pandemic
BioConnection B.V. / Oss, The Netherlands / April 9, 2020 BioConnection has sterile production capacity available for the battle against the Covid-19 pandemic BioConnection (established in 2005) is an independent CMO (Contract Manufacturing Organization) in Oss, The...
Lava Therapeutics and BioConnection cooperate to improve cancer treatment
BioConnection announces that Lava Therapeutics (LAVA), a biotechnology company creating and developing next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer, has selected BioConnection for GMP DP manufacturing. LAVA and BioConnection now...
Covid-19 update
Oss, The Netherlands, March 18, 2020. BioConnection has taken precautions related to the global outbreak of the Covid-19 virus. To start with; we are currently in full operation and running on-schedule with regard to our planned productions. Our production department...
BioConnection invests in expansion of its current production capacity with a second production line
Oss, The Netherlands, April 8, 2019. BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the growing customer demand and to ensure its future company growth. BioConnection, Contract Manufacturing Organization (CMO),...
BioConnection further strengthens its position in the (bio) pharmaceutical CMO business by adding a Flexible GMP area to its current capabilities.
Oss, The Netherlands, March 13, 2019. BioConnection opens this month, after an intensive engineering and validation program its Flexible GMP area. The area consists of several small scale cleanrooms ranging from class B up to class D. The Flexible GMP area is located...
Interview Mibiton with BioConnection – February 2018
Interview Mibiton with Alexander Willemse - BioConnection - Download If you want to learn more about how BioConnection can bring value to your projects, please contact us. Alexander.Willemse@Bioconnection.eu Sjaak.Stevense@Bioconnection.eu
BioConnection wins FD Gazellen award
BioConnection, Contract Development and Manufacturing Organization, proudly announces that is has won the FD Gazellen status. This prestigious award is given by the Financieel Dagblad to financially healthy companies that have reached yearly revenue growth...